• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First report of dabigatran reversal in iatrogenic pericardial tamponade during catheter ablation of atrial fibrillation.

作者信息

Miller Jared D, Brinker Jeffrey A, Spragg David D

机构信息

Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

出版信息

HeartRhythm Case Rep. 2017 Oct 7;3(12):566-567. doi: 10.1016/j.hrcr.2017.07.006. eCollection 2017 Dec.

DOI:10.1016/j.hrcr.2017.07.006
PMID:29296576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5741803/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ce/5741803/7a5795f83016/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ce/5741803/4035ff9b33c5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ce/5741803/7a5795f83016/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ce/5741803/4035ff9b33c5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07ce/5741803/7a5795f83016/gr2.jpg

相似文献

1
First report of dabigatran reversal in iatrogenic pericardial tamponade during catheter ablation of atrial fibrillation.房颤导管消融术中医源性心包填塞时达比加群逆转的首例报告。
HeartRhythm Case Rep. 2017 Oct 7;3(12):566-567. doi: 10.1016/j.hrcr.2017.07.006. eCollection 2017 Dec.
2
Use of idarucizumab for dabigatran reversal in cardiac tamponade during atrial fibrillation ablation: A case report.艾达司珠单抗用于房颤消融术中心脏压塞时达比加群逆转：一例报告
J Cardiol Cases. 2019 May 10;20(1):27-29. doi: 10.1016/j.jccase.2019.03.004. eCollection 2019 Jul.
3
Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity.使用八因子旁路活性药物逆转心脏消融术时危及生命的出血的达比加群。
Crit Care Med. 2013 May;41(5):e42-6. doi: 10.1097/CCM.0b013e31827caaa3.
4
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.非桥接的达比加群酯与华法林用于房颤消融
N Engl J Med. 2017 Apr 27;376(17):1627-1636. doi: 10.1056/NEJMoa1701005. Epub 2017 Mar 19.
5
[Impact of different anticoagulation therapies on heparin dosage applied to atrial fibrillation patients undergoing atrial fibrillation catheter ablation].[不同抗凝治疗对接受心房颤动导管消融术的心房颤动患者肝素用量的影响]
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Aug 24;47(8):602-607. doi: 10.3760/cma.j.issn.0253-3758.2019.08.003.
6
Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.达比加群酯抗凝下房颤导管消融术中心脏压塞不停抗凝应用依达鲁珠单抗的临床经验。
J Thromb Thrombolysis. 2019 May;47(4):487-494. doi: 10.1007/s11239-019-01835-8.
7
Management of Periprocedural and Early Pericardial Effusions With Tamponade Following Ablation of Atrial Fibrillation With Uninterrupted Factor Xa Inhibitors: A Case Series.使用不间断因子Xa抑制剂消融心房颤动后围手术期和早期心包积液伴心脏压塞的管理：病例系列
J Cardiovasc Electrophysiol. 2016 Apr;27(4):399-403. doi: 10.1111/jce.12918. Epub 2016 Feb 17.
8
A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS score in Japan.基于日本CHADS评分的房颤导管消融联合华法林和达比加群的成本效用分析。
J Cardiol. 2017 Jan;69(1):89-97. doi: 10.1016/j.jjcc.2016.01.008. Epub 2016 Mar 2.
9
Periprocedural anticoagulation of patients undergoing pericardiocentesis for cardiac tamponade complicating catheter ablation of atrial fibrillation.因心房颤动导管消融术并发心脏压塞而接受心包穿刺术的患者的围手术期抗凝治疗。
Int Heart J. 2015;56(1):56-61. doi: 10.1536/ihj.14-158. Epub 2014 Dec 11.
10
Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.达比加群酯治疗心房颤动消融术相关卒中或短暂性脑缺血发作的风险的荟萃分析。
Am J Cardiol. 2014 Apr 1;113(7):1173-7. doi: 10.1016/j.amjcard.2013.12.027. Epub 2014 Jan 15.

引用本文的文献

1
The use of Intracardiac Echocardiography in Catheter Ablation of Atrial Fibrillation.心内超声心动图在心房颤动导管消融中的应用。
Curr Cardiol Rep. 2024 Sep;26(9):893-901. doi: 10.1007/s11886-024-02091-w. Epub 2024 Jul 12.
2
Use of idarucizumab for dabigatran reversal in cardiac tamponade during atrial fibrillation ablation: A case report.艾达司珠单抗用于房颤消融术中心脏压塞时达比加群逆转：一例报告
J Cardiol Cases. 2019 May 10;20(1):27-29. doi: 10.1016/j.jccase.2019.03.004. eCollection 2019 Jul.

本文引用的文献

1
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.2017年心房颤动导管消融与外科消融治疗专家共识声明：由心律学会（HRS）、欧洲心律协会（EHRA）、欧洲心血管病预防与康复协会（ECAS）、亚太心律学会（APHRS）及拉丁美洲心脏学会（SOLAECE）联合发布
Heart Rhythm. 2017 Oct;14(10):e275-e444. doi: 10.1016/j.hrthm.2017.05.012. Epub 2017 May 12.
2
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.非桥接的达比加群酯与华法林用于房颤消融
N Engl J Med. 2017 Apr 27;376(17):1627-1636. doi: 10.1056/NEJMoa1701005. Epub 2017 Mar 19.
3
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
4
Idarucizumab for Dabigatran Reversal.达比加群酯逆转剂依达鲁珠单抗。
N Engl J Med. 2015 Aug 6;373(6):511-20. doi: 10.1056/NEJMoa1502000. Epub 2015 Jun 22.
5
Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin.华法林抗凝治疗期间心房颤动消融术中心脏压塞的处理和结局。
Heart Rhythm. 2011 Jun;8(6):805-8. doi: 10.1016/j.hrthm.2011.01.020. Epub 2011 Jan 12.
6
Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.全球更新的关于人房颤导管消融方法、疗效和安全性的调查。
Circ Arrhythm Electrophysiol. 2010 Feb;3(1):32-8. doi: 10.1161/CIRCEP.109.859116. Epub 2009 Dec 7.
7
Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.全球人类心房颤动导管消融术的方法、疗效及安全性调查。
Circulation. 2005 Mar 8;111(9):1100-5. doi: 10.1161/01.CIR.0000157153.30978.67. Epub 2005 Feb 21.